Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [IR] SK hynix (000660 / SKHY) – Q1 2025 Earnings Presentation / 2025-04-24 IR Room
  • [Research] Samsung SDI (006400) – DS Investment & Securities | ESS Revenue Surge · 4Q26 Turnaround · Physical AI Expansion with 46-Series & All-Solid-State / 2026-02-03 Research
  • [Research] Samsung SDI (006400) – DS Investment & Securities | 4Q Turnaround Visibility · Non-PFE LFP ESS · European Volume Models / 2026-04-29 Research
  • [Research] Hanwha Ocean (042660) – Eugene | High-Price Order Mix · Merchant Margin Continuity · Special Ship Pipeline / 2026-07-28 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Keytruda SC Growth Accelerates · Favorable Contract Terms · Early June PGR Catalysts / 2026-05-11 Research
  • [Research] Alteogen (196170) – Hana Securities | New ALT-B4 Deal Signed · Qlex Prescription Surge · SC Conversion Acceleration / 2026-08-06 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · SOX Inclusion · HBM Pricing / 2026-06-25 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q4 2025 Earnings Presentation / 2026-01-23 IR Room

[Research] LIG D&A (079550) – SK Securities | CapEx Expansion · Global Interceptor Shortage · Earnings Quality / 2026-08-10

Posted on August 10, 2026August 21, 2026 By ksb220805@gmail.com

Brokerage : SK Securities

Analyst : Shane Han, RA: Seoyoung Ko

Investment Rating : BUY (Maintain)

Target Price : KRW 1,300,000 (Upward)

Core Momentum : Production capacity expansion at Gumi and Gimcheon plants signaling advancing export contracts amid a global interceptor shortage, paving the way for qualitative earnings growth in 2028-2029

📊 1. [Valuation & Key Financial Metrics]

  • Investment Rating & Target Price: Rating BUY (Maintain), Target Price KRW 1,300,000 (Upward from KRW 1,150,000), Current Price KRW 741,000 (As of 2026-08-07), Upside Potential 75.4%
  • Rationale for Target Price Revision: Incorporates visible volume (Q) and price (P) expansion scheduled for 2028-2029, anchored by strategic CapEx additions responding to the global interceptor shortage
  • 2026 Full-Year Earnings Forecast Revisions & Guidance:
    • 2026 Revised Forecast: Revenue KRW 4,847 Billion, Operating Profit KRW 443 Billion (OP Margin 9.1%), Controlling Net Profit KRW 377 Billion (Net Margin 7.8%)
    • 2026 Previous Forecast: Revenue KRW 5,065 Billion, Operating Profit KRW 469 Billion (OP Margin 9.3%), Controlling Net Profit KRW 371 Billion (Net Margin 7.3%)
    • 2026 Consensus: Revenue KRW 5,138 Billion, Operating Profit KRW 461 Billion (OP Margin 9.0%), Controlling Net Profit KRW 380 Billion (Net Margin 7.4%)
    • Full-Year Guidance Upgrade: Upward revision of annual full-year corporate OPM guidance from 7% to 8% based on robust 1H26 profitability
  • Stock Indicators: KOSPI 6,258.77pt, Market Cap KRW 16,302 Billion, Outstanding Shares 22.0 Million shares, 52-Week High KRW 1,020,000, 60-Day Avg Daily Trading Value KRW 162 Billion, Foreign Ownership 26.46%, Major Shareholders LIG & 8 affiliated parties (38.21%), National Pension Service (10.31%)

🚀 2. [Market Opportunities & Business Outlook]

  • 2Q26 Earnings Review:
    • Consolidated revenue reached KRW 1,110.1 Billion (+17.4% YoY, -4.9% QoQ), operating profit recorded KRW 105.7 Billion (+29.6% YoY, -38.2% QoQ, OPM 9.5%), and controlling net profit reached KRW 97 Billion, meeting market consensus (KRW 110.5 Billion operating profit).
    • Profitability was driven by an expanding export mix without one-off gains. Domestic OPM held at 9-10% for mass production and BEP for R&D.
    • 2Q UAE Cheongung revenue totaled approximately KRW 99 Billion (normalizing from 1Q’s early deliveries and spare parts), expected to recover to around KRW 120 Billion quarterly in 2H, surpassing KRW 500 Billion annually in 2026.
    • Ghost Robotics recorded an operating loss of KRW 12 Billion in 2Q but is projected to achieve BEP next year.
  • Industry Environment & Strategic CapEx Implications:
    • Accelerating air defense demand across the Middle East (Iran conflict), growing Southeast Asian interest (Malaysia, Indonesia, Philippines) in Cheongung-II, and European export potential via Rheinmetall JV MOU.
    • Capacity additions at the Gumi and Gimcheon production facilities signify concrete progress in export contract negotiations and high order visibility rather than purely speculative CapEx.

📝 Editor’s Comment (Perspective)

The covering analyst views LIG D&A not as a company exposed to quarterly shipment fluctuations, but as a top-tier defense exporter that is translating the global interceptor shortage into secured order pipelines and structural capacity expansion for 2028-2029. This perspective prioritizes the strategic implications of the Gumi and Gimcheon plant expansions and broad geographic diversification (Middle East, Southeast Asia, Europe) over short-term quarterly earnings comparisons.

To verify whether this investment thesis continues to materialize, primary focus should be directed toward the execution pace and operational ramp-up of the Gumi and Gimcheon facility expansions, the recovery of UAE Cheongung quarterly revenue to the KRW 120 Billion level in 2H, and the formal signing of new export contracts across Southeast Asia and Europe via the Rheinmetall JV. These operational milestones can be monitored through future quarterly earnings releases, corporate IR disclosures, contract award filings, and official periodic reports.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Defense

Post navigation

Previous Post: [Research] LIG D&A (079550) – Daishin Securities | 2Q26 Review · Backlog Realization · Export Margin Expansion / 2026-08-10
Next Post: [Research] Alteogen (196170) – Daishin Securities | Keytruda Qlex Commercial Milestones · RNA Modality Expansion · Platform Re-rating / 2026-08-10

Related Posts

  • [Research] Samsung Biologics (207940) – DS Investment & Securities | Plant 5 Revenue Contribution · US Plant Acquisition · Plant 6 Groundbreaking / 2026-04-23 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Legacy Memory Pricing · LTA · ADR / 2026-02-23 Research
  • [Research] Hanwha Ocean (042660) – Shinhan | Merchant Profit Level-Up · Special Ship Order Variables · Balanced Portfolio / 2026-07-28 Research
  • [Research] Hanwha Ocean (042660) – DS Investment & Securities | Low-Price Mix Reduction · Merchant Margin Step-Up · MASGA & Defense Pipeline / 2026-04-28 Research
  • [Research] ABL Bio (298380) – DS Investment & Securities | ABL001 Data Failure · Grabody Platforms · Intrinsic Value / 2026-04-28 Research
  • [Research] Samsung Biologics (207940) – iM Securities | US Site Operation · K-CDMO Policy Support · Order Pipeline Optimization / 2026-04-23 Research
  • [Research] LIG D&A (079550) – Kiwoom Securities | K-Defense Competitiveness · Pipeline Expansion · Rheinmetall JV / 2026-06-17 Research
  • [Research] Samsung SDI (006400) – Hana Securities | North America JV Resolution · ESS Line Conversion · Earnings Estimate Upgrades / 2026-08-12 Research
  • [Research] Samsung Biologics (207940) – Shinhan Securities | Rockville Revenue Recognition · Guidance Revision Potential · Songdo Plant 6 Groundbreaking / 2026-04-23 Research
  • [Research] SK hynix (000660 / SKHY) – Eugene Investment | Server Memory Demand · LTA · HBM Leadership / 2026-05-04 Research
  • [Research] Alteogen (196170) – Shinhan Securities | First UK Patent Ruling Favors Merck · Positive Read-across to Global Disputes · Pipeline Out-Licensing Ahead / 2026-02-23 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Record 3 Out-Licensing Deals in 2026 · Rapid Keytruda SC Rollout · H2 Clinical Pipeline Catalysts / 2026-08-06 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | MLCC Price Hikes · Server Product Mix · Target Price Revision / 2026-07-31 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Keytruda SC Growth Accelerates · Favorable Contract Terms · Early June PGR Catalysts / 2026-05-11 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme